Health House International has begun a non-interventional observational study in Germany examining the effect of its cannabis extracts on quality of life of patients and their safety and tolerability.
Launched by CanPharma and supported by Kalapa Clinic, both 100% owned by Health House, the results from the 600-patient study will assist in improving the knowledge and confidence of medical professionals when prescribing cannabis extracts.
Health House CEO, David Attwood, commented: “As a leader in the field of medicinal cannabis, we recognise that due to the limited historical data currently available on the medical use of cannabis, practitioners face uncertainty when it comes to prescribing.
“Optimal patient care needs medical progress as well as professional education. In cooperation with leading experts, CanPharma is working to advance the clinical evidence for the use and effectiveness of cannabis-based medicines.”
The study will be using CanPharma’s full-spectrum cannabis extracts and will run for two years, with the first interim results expected in approximately six months.
The analysis of data sets collected from patients will support treatment safety as well as the ongoing improvement and standardisation of individualised cannabinoid therapy, and the individual observation period for each participant is six months.
Dr Henrik Sprengel, executive director of Health House and CEO of CanPharma, added: “Cannabis treatment must be tailored to the individual needs of patients. Gaining knowledge about the safety and tolerability of our cannabis extracts under everyday conditions is an important task that will drive confidence of medical professionals in prescribing.
“We are pleased and proud to be doing pioneering work here and to be driving the acquisition of scientific data.”
The observational study is being conducted by the first medical cannabis counselling centre to be established in Europe – the Kalapa Clinic – an independent part of the Health House group.
[activecampaign form=31]
